Psyence Biomedical Past Earnings Performance
Past criteria checks 0/6
Psyence Biomedical's earnings have been declining at an average annual rate of -1495.5%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-1,495.5%
Earnings growth rate
-1,124.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Psyence Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -51 | 2 | 1 |
| 31 Dec 23 | 0 | -28 | 2 | 2 |
| 31 Mar 23 | 0 | -3 | 2 | 2 |
Quality Earnings: PBM is currently unprofitable.
Growing Profit Margin: PBM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PBM's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PBM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PBM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: PBM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.